BerandaPHS • FRA
add
Photocure ASA
Tutup sebelumnya
€4,20
Rentang hari
€4,16 - €4,16
Rentang tahun
€4,01 - €6,13
Rasio P/E
-
Hasil dividen
-
Berita pasar
IDX Channel
29 menit yang lalu
Wall Street Ditutup Mixed, S&P Melemah Tertekan Imbal Hasil Treasury AS
0,80%
0,18%
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (NOK) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 145,45 jt | 0,78% |
Biaya operasional | 117,16 jt | -2,85% |
Laba bersih | 12,33 jt | 186,06% |
Margin laba bersih | 8,48 | 183,61% |
Penghasilan per saham | 0,45 | 181,25% |
EBITDA | 27,85 jt | 19,06% |
Tarif pajak efektif | 23,70% | — |
Neraca
Total aset
Total liabilitas
| (NOK) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 266,99 jt | 3,11% |
Total aset | 713,58 jt | 0,99% |
Total liabilitas | 213,92 jt | -10,51% |
Total ekuitas | 499,66 jt | — |
Saham yang beredar | 27,11 jt | — |
Harga terhadap nilai buku | 0,23 | — |
Tingkat pengembalian aset | 7,23% | — |
Tingkat pengembalian modal | 10,18% | — |
Arus Kas
Perubahan kas bersih
| (NOK) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 12,33 jt | 186,06% |
Kas dari operasi | 19,52 jt | -32,96% |
Kas dari investasi | 472,00 rb | 265,89% |
Kas dari pembiayaan | -11,27 jt | 31,02% |
Perubahan kas bersih | 8,72 jt | -32,43% |
Arus kas bebas | 5,25 jt | -65,93% |
Tentang
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
Didirikan
1993
Situs
Karyawan
102
